Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API

IMGN
Immunogen Inc
stock NASDAQ

Inactive
Feb 9, 2024
31.23USD0.000%(0.00)48,606,862
Pre-market
0.00USD-100.000%(-31.23)0
After-hours
0.00USD0.000%(0.00)0
OverviewOption ChainMax PainOptionsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Jan 31, 2022
06:33AM EST  ImmunoGen Appoints Mimi Huizinga As SVP And Head Of Medical Affairs   RTTNews
06:30AM EST  ImmunoGen Appoints Mimi Huizinga, MD, as Senior Vice President and Head of Medical Affairs   Business Wire
Jan 3, 2022
04:30PM EST  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Dec 29, 2021
04:30PM EST  ImmunoGen Announces Webcast of Presentation and Q&A at the 40th Annual J.P. Morgan Healthcare Conference   Business Wire
Dec 14, 2021
09:14AM EST  ImmunoGen Granted U.S Patent #11,198,736 'Method for identifying an ovarian cancer in a subject likely to respond to anti-folate receptor 1 (FOLR1) antibody'   Benzinga
Dec 12, 2021
09:51AM EST  ImmunoGen Presented Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza and Venclexta in Relapsed/Refractory Acute Myeloid Leukemia at ASH 2021; Said Triplet Data Demonstrating Manageable Safety Profile and Promising Anti-Leukemia Activity Highlighted in Oral Presentation   Benzinga
09:38AM EST  ImmunoGen Presents Initial Findings From Phase 1b/2 Study Of IMGN632 With Vidaza And Venclexta In R/R AML At ASH   RTTNews
09:30AM EST  ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza(r) and Venclexta(r) in Relapsed/Refractory Acute Myeloid Leukemia at ASH   Business Wire
Dec 6, 2021
04:01PM EST  ImmunoGen Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares   Business Wire
06:07AM EST  The Week Ahead In Biotech (Dec. 6-Dec. 11): Dar FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More   Benzinga
Dec 2, 2021
06:09AM EST  ImmunoGen Priced Upsized Public Offering of 11.6M Share of Common Stock @$6.60/Share   Benzinga
12:55AM EST  ImmunoGen Inc. (IMGN), a cancer treatment provider, on Thursday, announced the pricing of its upsized public offering of 11.63 million common shares at $6.60 per share.   RTTNews
12:16AM EST  ImmunoGen Announces Pricing Of 11.64 Mln Shares At $6.60/Shr   RTTNews
12:00AM EST  ImmunoGen Announces Pricing of Upsized Public Offering of Common Stock   Business Wire
Dec 1, 2021
10:08AM EST  Benzinga's Top Ratings Upgrades, Downgrades For December 1, 2021   Benzinga
08:41AM EST  The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment; Regulatory Setbacks For CTI Biopharma, BioXcel; Favorable Ruling For Viatris In Tecfidera Patent Case   Benzinga
08:36AM EST  The Daily Biotech Pulse: Adcom Backs Merck's Oral COVID-19 Treatment, Regulatory Setbacks For CTI Biopharma, Favorable Ruling For BioXcel, Viatris In Tecfidera Patent Case   Benzinga
08:12AM EST  10 Biggest Price Target Changes For Wednesday   Benzinga
06:10AM EST  A Peek Into The Markets: US Stock Futures Higher Ahead Of ADP, Manufacturing Data   Benzinga
04:57AM EST  Jefferies Upgrades Immunogen to Buy, Raises Price Target to $12   Benzinga
Nov 30, 2021
05:03PM EST  ImmunoGen Announces Proposed Public Offering Of $175M Of Common Stock   Benzinga
05:00PM EST  Mid-Afternoon Market Update: Dow Dips 500 Points; ImmunoGen Shares Spike Higher   Benzinga
04:56PM EST  Mid-Day Market Update: Barnes & Noble Education Drops Following Q2 Results; Cumberland Pharmaceuticals Shares Jump   Benzinga
04:47PM EST  The Daily Biotech Pulse: Cumberland Jumps On FDA Nod, Regeneron Says Antibody Treatment May Be Less Effective Against Omicron, ImmunoGen Readout   Benzinga
04:44PM EST  Immunogen Down 6% In After-market Trade On Public Stock   RTTNews
04:42PM EST  ImmunoGen Announces Top-Line Results From Pivotal SORAYA Trial Of Mirvetuximab Soravtansine In Ovarian Cancer; Trial Met Primary Endpoint With Confirmed Objective Response Rate Of 32.4%   Benzinga
04:01PM EST  ImmunoGen Announces Proposed Public Offering of Common Stock   Business Wire
06:35AM EST  ImmunoGen Unveils Positive Top-Line Results From Pivotal SORAYA Trial Of Mirvetuximab Soravtansine In Ovarian Cancer   RTTNews
06:30AM EST  ImmunoGen Announces Positive Top-Line Results from Pivotal SORAYA Trial of Mirvetuximab Soravtansine in Ovarian Cancer   Business Wire
Nov 24, 2021
04:30PM EST  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Nov 17, 2021
04:05PM EST  ImmunoGen Appoints Tracey McCain To Its Board Of Directors   RTTNews
04:01PM EST  ImmunoGen Appoints Tracey L. McCain, Esq. to Its Board of Directors   Business Wire
Nov 16, 2021
04:30PM EST  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
06:35AM EST  ImmunoGen Appoints Kristen Harrington-Smith As SVP And Chief Commercial Officer   RTTNews
06:31AM EST  ImmunoGen Appoints Kristen Harrington-Smith as Senior Vice President and Chief Commercial Officer   Business Wire
Nov 4, 2021
09:00AM EDT  ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza(r) and Venclexta(r) in Relapsed/Refractory Acute Myeloid Leukemia at ASH   Business Wire
Nov 1, 2021
08:03PM EDT  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Oct 29, 2021
11:57AM EDT  SVB Leerink Maintains Market Perform on Immunogen, Lowers Price Target to $5   Benzinga
08:00AM EDT  The Daily Biotech Pulse: Gilead-Merck Collaborate For Breast Cancer Study, Decision Day For ANI Pharma, Pfizer Gets Canadian Regulatory Nod, 3 IPOs   Benzinga
07:14AM EDT  Recap: Immunogen Q3 Earnings   Benzinga
06:37AM EDT  ImmunoGen Q3 Net Loss $37.3 Mln Vs $22.4 Mln Last Year   RTTNews
06:35AM EDT  Immunogen Q3 EPS $(0.18), Inline, Sales $9.20M Miss $19.03M Estimate   Benzinga
06:30AM EDT  ImmunoGen Reports Recent Progress and Third Quarter 2021 Financial Results   Business Wire
03:41AM EDT  Earnings Scheduled For October 29, 2021   Benzinga
Oct 28, 2021
11:45AM EDT  Earnings Outlook For Immunogen   Benzinga
Oct 24, 2021
11:45AM EDT  The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More   Benzinga
Oct 18, 2021
12:56PM EDT  Immunogen Option Alert: Nov 19 $6 Calls Sweep (14) near the Ask: 439 @ $0.651 vs 2863 OI; Earnings 10/29 Before Open Ref=$5.77   Benzinga
Oct 14, 2021
04:01PM EDT  ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2021 Operating Results   Business Wire
Oct 1, 2021
04:30PM EDT  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Sep 22, 2021
04:07PM EDT  ImmunoGen Appoints Helen Thackray To Its Board Of Directors   RTTNews
04:01PM EDT  ImmunoGen Appoints Helen M. Thackray, MD to its Board of Directors   Business Wire
Sep 13, 2021
09:46AM EDT  ImmunoGen Sponsored Study Titled 'Open-Label Study to Evaluate Mirvetuximab Soravtansine in Cancers With High Folate Receptor-Alpha Expression' Posted To ClinicalTrials.Gov; Study Is Recruiting   Benzinga
Aug 2, 2021
04:30PM EDT  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Jul 30, 2021
07:54AM EDT  The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs   Benzinga
07:04AM EDT  Recap: Immunogen Q2 Earnings   Benzinga
06:41AM EDT  ImmunoGen Reaffirms FY21 Sales $65M-$75M vs $69.3M Estimate   Benzinga
06:40AM EDT  Immunogen Q2 EPS $(0.15) Beats $(0.18) Estimate, Sales $16.90M Miss $18.92M Estimate   Benzinga
06:38AM EDT  ImmunoGen Q2 Net Loss $30.7 Mln Vs. Net Loss $24.3 Mln Last Year   RTTNews
06:30AM EDT  ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results   Business Wire
04:13AM EDT  Earnings Scheduled For July 30, 2021   Benzinga
Jul 25, 2021
10:05AM EDT  The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More   Benzinga
Jul 15, 2021
04:02PM EDT  ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2021 Operating Results   Business Wire
Jul 1, 2021
04:30PM EDT  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Jun 23, 2021
10:47AM EDT  Immunogen Insights: Return On Capital Employed   Benzinga
Jun 1, 2021
04:30PM EDT  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
May 20, 2021
04:30PM EDT  ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual Healthcare Conference   Business Wire
May 19, 2021
05:25PM EDT  Pharma/Biotech Companies Highlight Upcoming Presentations At American Society Of Clinical Oncology Jun. 4-8, 2021   Benzinga
05:00PM EDT  ImmunoGen Announces Mature Data from FORWARD II Study Evaluating Mirvetuximab Soravtansine in Combination with Avastin(r) in Recurrent Ovarian Cancer, Regardless of Platinum Status   Business Wire
May 10, 2021
07:08AM EDT  Immunogen: Q1 Earnings Insights   Benzinga
06:35AM EDT  ImmunoGen Q1 Revenues $15.7 Mln Vs. $13.3 Mln Last Year   RTTNews
06:32AM EDT  Immunogen Q1 EPS $(0.17) Beats $(0.19) Estimate, Sales $15.70M Miss $17.73M Estimate   Benzinga
06:30AM EDT  ImmunoGen Reports Recent Progress and First Quarter 2021 Financial Results   Business Wire
04:09AM EDT  Earnings Scheduled For May 10, 2021   Benzinga
May 3, 2021
04:30PM EDT  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Apr 26, 2021
04:01PM EDT  ImmunoGen Announces Conference Call to Discuss Its First Quarter 2021 Operating Results   Business Wire
Apr 12, 2021
09:59AM EDT  Immunogen Saturday Morning Announced Preclinical Data On IMGC936 At American Association For Cancer Research Conference   Benzinga
Apr 10, 2021
08:30AM EDT  ImmunoGen Presents Preclinical Data on IMGC936 at the AACR Virtual Annual Meeting   Business Wire
Apr 8, 2021
10:56AM EDT  ImmunoGen US Patent & Trademark Office Abstract For Co.'s 'SELECTIVE SULFONATION OF BENZODIAZEPINE DERIVATIVES'   Benzinga
Apr 1, 2021
04:30PM EDT  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Feb 24, 2021
04:30PM EST  ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Life Sciences Conference   Business Wire
Feb 12, 2021
10:08AM EST  Earnings Scheduled For February 12, 2021   Benzinga
08:44AM EST  Recap: Immunogen Q4 Earnings   Benzinga
06:37AM EST  ImmunoGen Q4 Net Income $31.4 Mln Or $0.16/Shr Vs $4.8 Mln Or $0.03/Shr Last Year   RTTNews
06:31AM EST  ImmunoGen Sees FY21 Sales $65M-$75M vs $53M Estimate   Benzinga
06:31AM EST  Immunogen Q4 EPS $0.16 Up From $0.03 YoY, Sales $85.80M Up From $44.86M YoY   Benzinga
06:30AM EST  ImmunoGen Reports Recent Progress and 2020 Financial Results   Business Wire
04:37AM EST  Earnings Scheduled For February 12, 2021   Benzinga
Feb 11, 2021
04:30PM EST  ImmunoGen Announces Webcast of Presentation at Upcoming SVB Leerink 10th Annual Global Healthcare Conference   Business Wire
Feb 9, 2021
08:10AM EST  The Daily Biotech Pulse: Dynavax Poaches GSK Vaccine Exec, KalVista Jumps On Data Readout, Corcept Issues Negative Preannouncement   Benzinga
Feb 6, 2021
12:42PM EST  The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight   Benzinga
Feb 1, 2021
04:30PM EST  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Jan 29, 2021
04:01PM EST  ImmunoGen Announces Conference Call to Discuss Its 2020 Operating Results   Business Wire
Jan 20, 2021
07:32AM EST  The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study   Benzinga
Jan 5, 2021
08:39AM EST  The Daily Biotech Pulse: Moderna Coronavirus Vaccine Receives Third Regulatory Nod, Gritstone Rallies On Hedge Fund Stake, aTyr's COVID-19 Drug Data   Benzinga
Jan 4, 2021
04:30PM EST  ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Dec 30, 2020
04:30PM EST  ImmunoGen Announces Webcast of Presentation and Q&A at the 39th Annual J.P. Morgan Healthcare Conference   Business Wire
Dec 18, 2020
04:49PM EST  Immunogen Files For Potential Mixed Shelf; Size Not Disclosed   Benzinga
Dec 15, 2020
07:52AM EST  The Daily Biotech Pulse: Mesoblast Releases Mixed Data, MediWound Jumps On Distribution Deal, Kezar Life Sciences Rallies On Index Inclusion, Opiant Gets BARA Funding   Benzinga
Dec 5, 2020
03:01PM EST  ImmunoGen Presents Updated Findings from Phase 1/2 Study of IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm at ASH Annual Meeting   Business Wire
Dec 1, 2020
04:30PM EST  ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Nov 30, 2020
04:31PM EST  ImmunoGen Announces Conference Call To Discuss Recent Updates For IMGN632 In Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Myeloid Leukemia; Call Set For Dec. 7, 2020   Benzinga
04:30PM EST  ImmunoGen Announces Conference Call to Discuss Recent Updates for IMGN632 in Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukemia   Business Wire
Nov 29, 2020
08:59AM EST  The Week Ahead In Biotech: Hematology Conference Gets Underway, Vanda And BioCryst Await FDA Decisions   Benzinga
Nov 18, 2020
04:30PM EST  ImmunoGen Announces Webcasts of Presentations at Upcoming Virtual Conferences   Business Wire
Nov 17, 2020
12:34PM EST  UPDATE: FDA AccessData.gov Listing Shows ImmunoGen's Blastic Plasmacytoid Dendritic Cell Neoplasm Treatment Designated For Orphan Status But Not FDA Approved For Orphan Indication   Benzinga
Nov 6, 2020
10:52AM EST  SVB Leerink Maintains Market Perform on Immunogen, Raises Price Target to $6   Benzinga
07:52AM EST  Recap: Immunogen Q3 Earnings   Benzinga
07:47AM EST  The Daily Biotech Pulse: Novartis Drug Flunks COVID-19 Study, Molecular Templates' Blood Cancer Study Placed On Partial Hold   Benzinga
06:43AM EST  ImmunoGen Q3 Net Loss $22.4 Mln Or $0.13/shr Vs. Net Loss Of $21.8 Mln Or $0.15/shr Prior Year   RTTNews
06:34AM EST  ImmunoGen Sees FY20 Sales $60M-$65M vs $67M Estimate   Benzinga
06:34AM EST  Immunogen Q3 EPS $(0.13) Beats $(0.18) Estimate, Sales $18.20M Beat $15.36M Estimate   Benzinga
06:32AM EST  ImmunoGen Reports Recent Progress and Third Quarter 2020 Financial Results   Business Wire
03:33AM EST  Earnings Scheduled For November 6, 2020   Benzinga
Nov 5, 2020
10:10AM EST  Earnings Outlook for Immunogen   Benzinga
Nov 4, 2020
04:30PM EST  ImmunoGen Announces Webcast of Presentation at Upcoming Jefferies Virtual London Healthcare Conference   Business Wire
Nov 2, 2020
04:30PM EST  ImmunoGen Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Oct 26, 2020
06:49AM EDT  HC Wainwright & Co. Assumes Immunogen at Buy, Announces Price Target of $11   Benzinga
Oct 22, 2020
04:01PM EDT  ImmunoGen Announces Conference Call to Discuss Its Third Quarter 2020 Operating Results   Business Wire
Oct 19, 2020
11:15AM EDT  ImmunoGen shares are trading higher after the company reported a strategic collaboration with Huadong Medicine to develop and commercialize mirvetuximab soravtansine in Greater China.   Benzinga
08:51AM EDT  ImmunoGen, Huadong Medicine Announce Strategic Collaboration To Develop, Commercialize Mirvetuximab Soravtansine   RTTNews
08:45AM EDT  ImmunoGen Reports Strategic Collaboration With Huadong Medicine To Develop, Commercialize Mirvetuximab Soravtansine In Greater China   Benzinga
08:45AM EDT  ImmunoGen and Huadong Medicine Announce Strategic Collaboration to Develop and Commercialize Mirvetuximab Soravtansine in Greater China   Business Wire
Oct 12, 2020
06:31AM EDT  ImmunoGen Raises $54.8M in Gross Proceeds Through its At-the-Market Facility   Benzinga
06:30AM EDT  ImmunoGen Raises $54.8 Million in Gross Proceeds Through its At-the-Market Facility   Business Wire
Oct 6, 2020
08:08AM EDT  10 Biggest Price Target Changes For Tuesday   Benzinga
05:22AM EDT  SVB Leerink Maintains Market Perform on Immunogen, Raises Price Target to $5   Benzinga
Oct 5, 2020
09:52AM EDT  Looking Into Immunogen's Return On Capital Employed   Benzinga
08:21AM EDT  Benzinga Pro's Top 5 Stocks To Watch For Monday, Oct. 5, 2020: REGN, DKNG, BWA, IMGN, FUBO   Benzinga
06:38AM EDT  ImmunoGen Announces FDA Breakthrough Therapy Designation For IMGN632   RTTNews
06:31AM EDT  ImmunoGen Announces FDA Breakthrough Therapy Designation for IMGN632 in Relapsed or Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm   Benzinga
Oct 2, 2020
10:39AM EDT  Benzinga's Top Upgrades, Downgrades For October 2, 2020   Benzinga
07:15AM EDT  Guggenheim Upgrades Immunogen to Buy   Benzinga
Oct 1, 2020
04:30PM EDT  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Sep 17, 2020
03:04AM EDT  ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort   RTTNews
03:01AM EDT  ImmunoGen Presents Final Data From Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination With Carboplatin and Avastin(r) at ESMO   Business Wire
Sep 2, 2020
04:30PM EDT  ImmunoGen Announces Webcast of Presentation at Upcoming H.C. Wainwright Virtual Global Investment Conference   Business Wire
Sep 1, 2020
04:33PM EDT  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Benzinga
Jul 31, 2020
09:53AM EDT  Immunogen shares are trading higher after the company reported better-than-expected Q2 EPS and sales results. UPDATE: Shares have since reversed.   Benzinga
07:34AM EDT  Immunogen: Q2 Earnings Insights   Benzinga
06:40AM EDT  ImmunoGen Q2 Net Loss $24.3 Mln Or $0.14/shr Vs. Net Loss $43.4 Mln Or $0.29/shr Last Year   RTTNews
06:34AM EDT  Immunogen Q2 EPS $(0.14) Beats $(0.17) Estimate, Sales $15.03M Beat $14.59M Estimate   Benzinga
06:30AM EDT  ImmunoGen Reports Recent Progress and Second Quarter 2020 Financial Results   Business Wire
04:15AM EDT  Earnings Scheduled For July 31, 2020   Benzinga
Jul 29, 2020
04:30PM EDT  ImmunoGen Announces Webcast of Presentation at Upcoming Canaccord Genuity Virtual Growth Conference   Business Wire
Jul 22, 2020
08:00AM EDT  ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)   Business Wire
Jul 20, 2020
07:06AM EDT  ImmunoGen Announces Susan Altschuller CFO   Benzinga
07:00AM EDT  ImmunoGen Appoints Susan Altschuller, PhD as Senior Vice President and Chief Financial Officer   Business Wire
Jul 16, 2020
04:01PM EDT  ImmunoGen Announces Conference Call to Discuss Its Second Quarter 2020 Operating Results   Business Wire


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC